Vyant Bio Reports First Quarter 2022 Results and Provides Strategic and Business Highlights
May 16, 2022 08:30 ET
|
Vyant Bio, Inc.
Conference Call and Webcast Today at 4:30 pm ET Scientific and Business Highlights ●Progress in the discovery of small molecule therapeutics to treat neurodevelopmental and...
Vyant Bio Reports Fourth Quarter and Year-End 2021 Results and Provides Strategic and Business Highlights
March 30, 2022 07:50 ET
|
Vyant Bio, Inc.
Highlights Focused as a pure-play drug discovery and development biotechnology companyPrimary work on the discovery of small molecule therapeutics to treat neurodevelopmental and neurodegenerative...
Vyant Bio and Cyclica Announce a Strategic Collaboration to Identify Compounds to Treat CDKL5 Deficiency Disorder
August 19, 2021 09:27 ET
|
Vyant Bio, Inc.
CDKL5 Deficiency Disorder (“CDD”) is a severe neurodevelopmental epileptic encephalopathy disorder with no effective treatments or cureCollaboration creates opportunities to identify, validate, and...